+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Adalimumab Biosimilar"

Systemic Idiopathic Juvenile Arthritis Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Systemic Idiopathic Juvenile Arthritis Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • September 2024
  • 97 Pages
  • Global
From
Behcet Disease Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Behcet Disease Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • August 2024
  • 82 Pages
  • Global
From
Adalimumab Biosimilar Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Adalimumab Biosimilar Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • August 2024
  • 95 Pages
  • Global
From
Axial Spondyloarthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Axial Spondyloarthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 145 Pages
  • Global
From
Ankylosing Spondylitis (Bekhterev's Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Ankylosing Spondylitis (Bekhterev's Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • October 2022
  • 140 Pages
  • Global
From
AbbVie Hit Harder By EU Humira Biosimilars Than Projected - Product Thumbnail Image

AbbVie Hit Harder By EU Humira Biosimilars Than Projected

  • Newsletter
  • April 2025
  • 3 Pages
  • Europe
From
Loading Indicator